Arbutus Biopharma Corp - FORM 10-K - EX-10.65 - EX 10.65 CYTOS TERMINATION - March 22, 2017

Attached files

file filename
EX-32.2 - EXHIBIT 32.2 CFO SOX - Arbutus Biopharma Corpexhibit322_soxcertcfo.htm
EX-32.1 - EXHIBIT 32.1 CEO SOX - Arbutus Biopharma Corpexhibit321_soxcertceo.htm
EX-31.2 - EXHIBIT 31.2 10-K CFO - Arbutus Biopharma Corpexhibit312_10-kcertcfo.htm
EX-31.1 - EXHIBIT 31.1 10K CEO - Arbutus Biopharma Corpexhibit311_10-kcertceo.htm
EX-23.1 - EXHIBIT 23.1 - Arbutus Biopharma Corpexhibit231_kpmgconsent.htm
EX-21.1 - EXHIBIT 21.1 - Arbutus Biopharma Corpexhibit211_listingofsubsid.htm
EX-10.67 - EX 10.67 ALEXION LICENSE AGREEMENT - Arbutus Biopharma Corpexhibit1067alexionagreemen.htm
EX-10.66 - EX 10.66 BILL SYMONDS EMPLOY AMEMD - Arbutus Biopharma Corpexhibit1066_billsymonds.htm
EX-10.64 - EX 10.64 DICERNA TERMINATION - Arbutus Biopharma Corpexhibit1064_dicernatermina.htm
EX-10.63 - EXHIBIT 10.63 NEUROVIVE TERMINATION - Arbutus Biopharma Corpexhibit1063_neurovivetermi.htm
EX-10.62 - EX 10.62 DOD TERMINATION - Arbutus Biopharma Corpexhibit1062_dodtermination.htm
10-K - 10-K - Arbutus Biopharma Corparbutus10k2016.htm


Exhibit 10.65


August 25, 2016

Didier Cowling
Chief Executive Officer
Kuros Biosciences AG
Wagistrasse 25
8952 Schlieren
Switzerland

Dear Mr. Cowling,

This letter constitutes written notice of termination by Arbutus Biopharma Inc., and its parent company Arbutus Pharma Corp. (collectively “Arbutus”) of the License Agreement by and between Cytos Biotechnology Ltd and Oncore Biopharma, Inc. (predecessor in interest of Arbutus), dated December 30, 2014 (“Agreement”), pursuant to § 12.3 (Termination of the Agreement for Convenience) of said Agreement.

Yours truly,
/s/ Elizabeth Howard
Elizabeth Howard
Executive Vice President & General Counsel

Cc:     VISCHER AG
Aeschenvorstadt 4
4010 Basel
Switzerland
Attn: Dr. Matthias Staehelin



Stock widget

Investing forum

Arbutus Biopharma Corp Reports